Halyard Health Inc. (HYH) Stock Rating Lowered by Zacks Investment Research
Halyard Health Inc. (NYSE:HYH) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “
A number of other brokerages have also recently weighed in on HYH. Deutsche Bank AG increased their target price on shares of Halyard Health from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, August 10th. TheStreet raised shares of Halyard Health from a “sell” rating to a “hold” rating in a report on Friday, July 8th. Finally, Stifel Nicolaus increased their target price on shares of Halyard Health from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, August 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $34.20.
Shares of Halyard Health (NYSE:HYH) traded up 0.17% during mid-day trading on Wednesday, hitting $34.45. 52,184 shares of the company traded hands. Halyard Health has a 52-week low of $22.76 and a 52-week high of $37.31. The firm has a 50-day moving average price of $35.30 and a 200 day moving average price of $32.61. The firm’s market cap is $1.61 billion.
Halyard Health (NYSE:HYH) last issued its earnings results on Wednesday, August 3rd. The company reported $0.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.09. The company had revenue of $400 million for the quarter, compared to analysts’ expectations of $383.08 million. Halyard Health had a negative net margin of 27.63% and a positive return on equity of 8.91%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.52 earnings per share. Equities research analysts anticipate that Halyard Health will post $1.82 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of HYH. Norges Bank bought a new position in shares of Halyard Health during the fourth quarter worth about $38,025,000. BlackRock Institutional Trust Company N.A. boosted its position in Halyard Health by 2.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,371,392 shares of the company’s stock worth $39,400,000 after buying an additional 28,541 shares in the last quarter. AXA acquired a new position in Halyard Health during the first quarter worth about $827,000. Paradice Investment Management LLC boosted its position in Halyard Health by 12.2% in the second quarter. Paradice Investment Management LLC now owns 1,357,237 shares of the company’s stock worth $44,137,000 after buying an additional 147,566 shares in the last quarter. Finally, Teachers Advisors Inc. boosted its position in Halyard Health by 5.9% in the first quarter. Teachers Advisors Inc. now owns 86,997 shares of the company’s stock worth $2,499,000 after buying an additional 4,850 shares in the last quarter. 82.94% of the stock is owned by institutional investors.
About Halyard Health
Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.